At the end of November 2023, the Medicines and Healthcare products Regulatory Agency published a UK-wide National Patient Safety Alert relating to the use of sodium valproate in men and women with epilepsy. Sue Thomas outlines the rationale for this and the implications for nurses ...
别名 [14C]-Sodium Valproate、Depakote ER、Divalproex + [13] 靶点 GABA receptor x Sodium channels 作用机制 GABA receptor激动剂(γ-氨基丁酸受体激动剂)、钠通道阻滞剂 治疗领域 神经系统疾病其他疾病 在研适应症 躁郁症偏头痛癫痫的复杂部分性发作+ [2] 非在研适应症 酒精相关疾病酗酒躁郁症1型+ [3] ...
Administration of a single oral 50 mg dose ofamitriptylineto 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports o...
Valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or death (e.g., migraine). ...
There is evidence that a number of anticonvulsants, such as phenytoin, valproate, and topiramate, also act by blocking the persistent sodium current, which is separate from the fast sodium current. Show moreView chapterExplore book Ion Channels William A Catterall, in Current Opinion in Physiology...
Valproate was first marketed in 1974, and risks of birth defects have been recognised since licensing. There have been regular patient safety alerts published by the Medicines and Healthcare products Regulatory Agency (MHRA) over the years, culminating in an alert (https://www.cas.mhra.gov.uk/...
Efficacy and safety of carbamazepine and sodium valproate and quality of life of the patient with complex partial seizureL., MaharjanH., Chhetri
The term valproate has been used to represent these medications. Drugs Affected By Phenytoin Table 3 includes commonly occurring drug interactions affected by phenytoin. However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The ...
plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. If the total daily dose exceeds 250 mg, it should be...
plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. If the total daily dose exceeds 250 mg, it should be...